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A recent report by Kalaany and Sabatini concerning mechanisms underlying the inhibitory effect of dietary
restriction on the growth of certain tumors adds to the evidence that insulin and IGF-I are hormones with
relevance to oncology.Recent progress in the field of ‘‘cancer
energetics’’ involves descriptions of the
influence of oncogenes and tumor
suppressor genes on the metabolic path-
ways used by cancer cells to generate
ATP (Jones and Thompson, 2009).
However, an important gap in knowledge
in this field involves an issue beyond the
cellular level—the influence of whole
organism energy balance on cancer
biology. The strong inhibitory effect of
host dietary restriction on the growth of
certain experimental tumors is a classic
observation that predates even Warburg’s
work concerning cancer energetics, yet
studies concerning the mechanisms
underlying this phenomenon are sparse.
A recent paper (Kalaany and Sabatini,
2009) provides important data which add
to prior evidence that the inhibitory effect
of dietary restriction on tumor growth is
attributable to the effect of the diet on
insulin and insulin-like growth factors
(Figure 1). They confirm that restriction of
food intake lowers both insulin and IGF-I
levels and show that the degree of in vitro
mitogenic responsivity of various cell lines
to insulin or IGF-I can be used to predict
which corresponding xenografts will be
growth inhibited in vivo by dietary restric-
tion. Furthermore, they demonstrate that
PI3 kinase-activating mutation or loss offunction of PTEN is sufficient to confer
resistance to the growth inhibitory effects
of dietary restriction.
A simple model to account for these
observations is that some cancers are
responsive to insulin and/or IGFs, and that
these neoplasms thrive when levels of
these mitogens are sufficient to contribute
to activation of the PI3K pathway. Many
studies are consistent with this hypothesis.
The implicated receptors are expressed by
many human cancers (e.g., Law et al.,
2008), and epidemiologic data (reviewed
in Pollak, 2008) provide evidence that high
circulating levels of the implicated ligands
are associated with adverse cancer prog-
nosis and/or increased cancer risk. Exam-
ples of consistent experimental data
include findings that tumor growth is
reduced in mice with mutations that lower
IGF-I levels (Majeed et al., 2005), and that
the growth inhibitory effect of caloric
restriction on a bladder cancer model can
be abolished by infusing IGF-I (Dunn
et al., 1997).
However, the simplest model may not
be complete. The dietary restriction
employed by Kalaany and Sabatini would
be expected to result in alterations in
additional hormones (such as leptin, adi-
ponectin, FGF21, and/or glucagon), and
an influence of these on neoplasms hasCell Metabonot been excluded. Additional work to
compare in vitro the influences of physio-
logic concentrations of these hormones
to those of insulin and IGF-I would be of
interest. Measurements at later time
points of in vivo changes in AKT pathway
activation within cancers as a function of
host diet would also be relevant, as some
data reported concern tumors less than
20 mm3.
Apart from the effects of dietary restric-
tion on the hormonal environment of
cancers, does it reduce energy supply to
the tumor? Kalaany and Sabatini do not
report changes in glucose, amino acids,
or fatty acids associated with the degree
of caloric restriction employed. Such
measurements would be of interest, but it
is likely that the host breaks down muscle
and fat at sufficient rates to maintain circu-
lating energy supply to normal tissues, and
to cancers. Therefore, host dietary restric-
tion may inhibit growth of certain cancers
through changes in hormone concentra-
tions rather than by causing energy deple-
tion at the cellular level.
What about the role of the energy sensor
AMP-activated kinase in tumor growth
inhibition by dietary restriction? In single-
cell organisms and in studies of cancer
cells in vitro, reduced supply of energy
sources leads toactivation ofAMPK, whichlism 9, May 6, 2009 ª2009 Elsevier Inc. 401
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Recent data from the Sabatini lab add to prior evidence suggesting that dietary restriction limits growth of
certain cancers through its effects on insulin and IGF-I, rather through reduced energy supply to cancer
cells. This is contributes to the rationale for investigations of novel cancer therapies that target insulin
and IGF-I signaling.inhibits energy-consuming processes
including proliferation in order to maximize
chance of survival. There is evidence that
AMPK withincancers can also beactivated
by host dietary restriction (Jiang et al.,
2008), but again this may be a conse-
quence more of hormonal activation of
AMPK than of a lack of energy supply to
cancer cells.
Is there clinical relevance to the results
of Kalaany and Sabatini? The concept
that one can deprive a cancer of energy
by starving the host seems far-fetched,
because as long as there is muscle or fat
to break down, the host will do all it can
to maintain blood glucose (to the tumor’s
advantage). However, if one accepts the
view that much of the effect of caloric
restriction is attributable to hormonal
changes such as reduced insulin rather
than to reduction in energy supply to
cancers, there are indeed medical implica-
tions.
Insulin and IGF-I signaling in cancer
cells, now strongly implicated by the Saba-
tini lab in the inhibitory effects of host
dietary restriction on cancer growth, had
already been identified as a potential target
for novel therapies (reviewed in Pollak,
2008).Dozensofdrugcandidates including
anti-receptor antibodies, anti-ligand anti-
bodies, and tyrosine kinase inhibitors with
varying degrees of specificity for members
of the insulin receptor family have been402 Cell Metabolism 9, May 6, 2009 ª2009shown to have antineoplastic activity in
preclinical models, and are being evalu-
ated in ongoing clinical trials (Pollak,
2008). The data reported by Kalaany and
Sabatini provide additional rationale for
these studies, as well for agents that act
downstream. One inconsistency deserves
attention: there is limited evidence that
agents that target insulin/IGF-I signaling
have activity even in cancers with PTEN
mutations (Burtrum et al., 2007), a result
that contrasts with the data of Kalaany
and Sabatini. This requires further study—
it may be that in certain contexts, loss of
function of PTEN results in hypersensitivity
to IGF or insulin receptor activation rather
than to constituitive, ligand-independent
pathway activation.
The results of Kalaany and Sabatini add
to the rationale for studies of the opposite
phenomenon: the stimulatory effect on
certain tumors of excess host energy
intake. This has public health implications,
given the obesity epidemic and the impact
of obesity on cancer mortality (Calle et al.,
2003). The same signaling system may be
involved: there is experimental evidence
that diet-induced hyperinsulinism may
activate insulin receptor signaling within
cancers (Venkateswaran et al., 2007),
raising the possibility that neoplasms of
patients who are obese and/or hyperinsu-
linemic may remain insulin sensitive, even
if their classic insulin target tissues areElsevier Inc.insulin resistant. In this context, AMPK
activators such as metformin deserve
study because of their insulin-lowering
activity—indeed, retrospective population
studies (reviewed in Pollak, 2008) have
associated metformin use with reduced
cancer mortality, and in a murine experi-
mental model, metformin abolished the
tumor growth acceleration associated
with high-energy diet (Algire et al., 2008).
AMPK activators have a separate ratio-
nale based on direct action on cancer
cells, which is associated with an antipro-
liferative effect (Zakikhani et al., 2008).
The experiments of Kalaany and Saba-
tini involved established cancers: exten-
sions to carcinogenesis models and the
prevention context will be of interest, as
pharmacologic or lifestyle measures to
avoid excess insulin or IGF stimulation of
at-risk tissues may also slow the process
of stepwise cellular transformation.
Historically, the field of ‘‘cancer endocri-
nology’’ involved studies of dependency
of subsets of breast and prostate cancer
on gonadal steroids, and this led to the
development of widely used and effective
cancer treatments. The data reported by
Kalaany and Sabatini add to prior
evidence suggesting that the paradigm
of hormonal dependence of neoplastic
growth may be extended to insulin and
IGFs.
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Excessive activation of the AT1A re
development of hypertension, diabe
levels of oxidative stress thanwild-t
aging process.
Persistent and poorly regulated hyperten-
sion is a major risk factor for many of the
most prevalent age-related disorders that
limit life span, including cardiovascular
disease,stroke,kidneydisease,andneuro-
degenerative diseases. Angiotensin II (Ang
II), a peptide produced from renin via the
proteolytic activity of angiotensin convert-
ing enzyme (ACE), is a key component of
an endocrine/paracrine signaling system
that increases vasoconstriction and blood
pressure. Ang II functionally interacts with
two forms of G protein-coupled receptor
(GPCR), the AT1 or AT2 type receptors.
The A subtype of the AT1 receptor
(AT1AR) is located on the surface of vas-
cular smooth muscle cells, and its activa-
tion by Ang II results in elevated levels of
intracellular calcium, generation of reactive
oxygen species (ROS), and contraction
of the cells. Ang II therefore acts to increase
vascular pressure, and accordingly ACE
inhibitors and AT1AR antagonists have
proven to be highly effective for the treat-
ment of hypertension (Werner et al., 2008).
As maintaining cardiovascular health can
have a major impact on longevity in hu-
mans, Benigni et al. (2009) recently exam-
ined the consequences of disruption of
the AT1AR gene on aging of the cardiovas-
cular and renal organ systems in mice.
Strikingly, both the average and maximum
life spans of AT1AR-deficient mice were
increased by approximately 20%.Bismar, T.A., and Pollak, M. (2005). Oncogene
24, 4736–4740.
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te on Aging Intramural Research Program, Balt
ceptor (AT1AR) by angiotensin II (Ang
tes, and kidney disease. AT1AR-defic
ypemice (Benigni et al., 2009), sugges
At a gross level the AT1AR-deficient mice
demonstrated no significant alteration in
body weight, fasting blood glucose, heart
weight/body weight ratio, or activity levels
demonstrating an ability of the animal to
partly mitigate the loss of AT1AR with
respect to overall energy metabolism.
However, age-related pathologies in the
cardiovascular system, including athero-
sclerotic lesions and cardiac fibrosis,
were reduced in AT1AR-deficient mice
compared to wild-type control mice
(Benigni et al., 2009). While the cellular
structure and function of the kidneys and
pancreas were unaffected by AT1AR defi-
ciency, age-related changes in the liver
(degeneration of hepatocytes, vesicular
steatosis, and exudation) were reduced
in the AT1AR-deficient mice. The aging
process involves damage to cells by
ROS, probably as the result of both
increased free radical production and a
reduced ability of cells to protect them-
selves against the ROS (Bokov et al.,
2004). To determine whether the increased
longevity of AT1AR-deficient mice was
associated with reduced levels of oxida-
tive stress, levels of nitrotyrosine, a marker
of oxidative attack on cellular proteins,
were measured in the heart, artery, and
kidney tissues from young and old wild-
type mice and aged AT1AR-deficient
mice. In all three tissues, levels of oxidative
protein damage were increased by aging
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II) is implicated in the age-related
ient mice live longer and have lower
ting a role for AT1AR signaling in the
in wild-type mice, but not in the AT1AR-
deficient mice. Benigni et al. used only
20 AT1A-deficient and 10 wild-type male
mice of one mixed genetic background
for their life span studies, an unusually
small number of animals for such a study.
It will therefore be important to repeat the
experiments with larger numbers of mice
of more than one genetic background;
females should also be evaluated, as there
may be sex differences in the effects of
AT1AR signaling on aging. In addition,
a comprehensive assessment of how
other blood-borne metabolic factors and
hormones also change in response to the
loss of Ang II signaling may also provide
insights into the longevity mechanism.
The low-level oxidative damage in old
AT1AR-deficient mice may not be due to
reduced production of ROS because
numbers of mitochondria, a major source
of free radicals, were increased in cells
from the AT1AR-deficient mice. Instead,
the authors’ data suggest that the lack
of AT1AR-mediated signaling results in
increased production of proteins that
protect cells against free radical attack.
Indeed, the expression of two cytoprotec-
tive mitochondrial proteins, Nampt and
sirtuin 3, were increased in kidney cells
of old AT1AR-deficient mice compared to
old wild-type mice (Benigni et al., 2009).
Nampt is a NAD+ biosynthetic enzyme
that protects cells against genotoxic
lism 9, May 6, 2009 ª2009 Elsevier Inc. 403
